EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention

Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott E Kasner, Jeffrey Saver, Jaime Masjuan, Andrew M Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov und 40 weitere

European Stroke Journal · 2026

DOI: 10.1093/esj/aakaf017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Stroke Journal, 2026. Verfasst von Mukul Sharma und 51 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada. Hauptthemen laut MEDLINE: Factor XIa, Fibrinolytic Agents, Ischemic Stroke, Secondary Prevention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Genetic deficiency of factor XI is associated with a reduced risk of ischemic stroke. Asundexian is a direct inhibitor of activated factor XIa (FXIa) with a low risk of bleeding in early trials. We seek to determine its efficacy and safety combined with antiplatelet therapy for prevention of ischemic stroke. Patients and methods Oral faCtor Eleven A iNhibitor asundexian as novel antithrombotiC (OCEANIC-STROKE) is a placebo-controlled, double-blind, event-driven randomised trial including participants with stroke (NIHSS ≤ 15) or high-risk TIA (ABCD2 6 or 7) within 72 h of onset. Participants had at least one of the following: atherosclerosis of extra- or intracranial vessels, a medical history of atherosclerosis or an imaged acute non-lacunar infarct. We excluded sources of stroke requiring anticoagulation and active non-trivial bleeding other than hemorrhagic infarction (HI 1 or 2). Participants received asundexian 50 mg daily or placebo stratified by planned concurrent antiplatelet therapy (single vs dual). The primary endpoint is time to ischemic stroke. We present baseline characteristics as of 5 June 2025.

Results

Between January 2023 and February 2025, we randomised 12,327 participants. Participants were 67% male with a mean (SD) age of 68 (11) years. Ischemic stroke was the index event for 95% of whom 27.4% had thrombolysis and/or mechanical thrombectomy. By TOAST classification, 43% of index strokes were LAA, 22% small vessel disease, 30% undetermined and 2% cardioembolic. Dual antiplatelets were planned in 63% as standard initial treatment. Trial completion is anticipated in October 2025.

Conclusion

OCEANIC-STROKE will be the first completed trial of FXIa inhibition for prevention of stroke after non-cardioembolic stroke or TIA.

Trial registration

ClinicalTrials.gov (NCT05686070).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XIaFibrinolytic AgentsIschemic StrokeSecondary PreventionStrokeAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodPlatelet Aggregation InhibitorsTreatment OutcomeRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

asundexianfactor XIpreventionrandomised trialstroke

Substanzen

Factor XIaFibrinolytic AgentsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada.
  • McMaster University, Department of Medicine, McMaster University, Hamilton, Canada.
  • Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Stroke and Cerebrovascular Medicine, Kyorin University, Tokyo, Japan.
  • Department of Neurology Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine at UCLA, Los Angeles, USA.

ORCID-Profile: Robin Lemmens, Hanne Christensen, Jukka Putaala, Lars Keller

Zitieren

APA

Sharma, M., Dong, Q., Hirano, T., Kasner, S. E., Saver, J., Masjuan, J., Demchuk, A. M., Cordonnier, C., Bereczki, D., Tsivgoulis, G., Veltkamp, R., Staikov, I., Bae, H. J., Campbell, B. C. V., Zini, A., Lee, I. H., Ameriso, S., Kovar, M., Mikulik, R., …, & Shoamanesh, A. (2026). Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention. European Stroke Journal. https://doi.org/10.1093/esj/aakaf017

Vancouver

Sharma M, Dong Q, Hirano T, Kasner SE, Saver J, Masjuan J, et al. Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention. European Stroke Journal. 2026. doi:10.1093/esj/aakaf017

BibTeX
@article{Sharma2026,
  author = {Sharma, Mukul and Dong, Qiang and Hirano, Teruyuki and Kasner, Scott E and Saver, Jeffrey and Masjuan, Jaime and Demchuk, Andrew M and Cordonnier, Charlotte and Bereczki, Daniel and Tsivgoulis, Georgios and Veltkamp, Roland and Staikov, Ivan and Bae, Hee-Joon and Campbell, Bruce C V and Zini, Andrea and Lee, I-Hui and Ameriso, Sebastian and Kovar, Martin and Mikulik, Robert and Lemmens, Robin and Ferro, José M and Robinson, Thompson and Christensen, Hanne and Ozturk, Serefnur and Leker, Ronen R and Turcani, Peter and Slowik, Agnieszka and Amaya, Pablo and Hoo, Fan Kee and De Marchis, Gian Marco and Knoflach, Michael and Sylaja, Pillai N and Putaala, Jukka and Coutinho, Jonathan M and Worp, H Bart van der and Miglane, Evija and Matijosaitis, Vaidas and Lindgren, Arne G and Silva, Gisele Sampaio and Sandset, Else Charlotte and Turuspekova, Saule Tleubergenovna and Joundi, Raed A and Schulze, Karleen and Shestakovska, Olga and Gilbride, Jennifer and Bangdiwala, Shrikant I and Xu, Lizhen and Muehlhofer, Eva and Colorado, Pablo and Mundl, Hardi and Keller, Lars and Shoamanesh, Ashkan},
  title = {Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention},
  journal = {European Stroke Journal},
  year = {2026},
  doi = {10.1093/esj/aakaf017}
}
Kostenlos starten →